Cardiology

113-128 of 306

CETP Inhibition and Obicetrapib: A New Era in Lipid Management
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
Cardiology
CETP Inhibition and Obicetrapib: A New Era in Lipid Management
- Kausik Ray, MBChB, MD, MPhil
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
Cardiology
CETP Inhibition With Obicetrapib: Implications for Cardiovascular Event Prevention
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
Cardiology
Latest Data Publication on Quantifying the Link Between TTR Response and Mortality Reduction
- Daniel Judge, MD
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
Cardiology
Redefining HF Care: The Role of Finerenone in Patients With LVEF ≥40% 
- Javed Butler, MD
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
Cardiology
Breaking New Ground: Acoramidis Reduces AF Events in ATTR CM Patients from ESC Heart Failure 2025
- Kevin Alexander, MD
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
Heart Matters
Timely ATTR-CM Diagnosis: Addressing Social Determinants of Health
- Kevin Alexander, MD
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
Heart Matters
Equitable Care for ATTR-CM: Improving Early Diagnosis in High-Risk Groups
- Kevin Alexander, MD
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
CME/CE
Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
0.50 credits
- Rajiv Agarwal, MBBS, MD, FASN, BRCU
- Amy Mottl, MD, MPH
- Muthiah Vaduganathan, MD, MPH
0.50 credits
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Heart Matters
Translating Patisiran’s 6-Minute Walk Test Gains into Real-Life Impact in ATTR-CM
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Heart Matters
Staging the Benefit: Tafamidis Outcomes in ATTR-CM Depend on Timing
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Heart Matters
Analyzing Outpatient Worsening Heart Failure in ATTR-CM
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
Heart Matters
Current and Emerging Treatments for Transthyretin Amyloid Cardiomyopathy
- Ahmad Masri, MD, MS
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
Heart Matters
Shared Decision-Making in Transthyretin Amyloid Cardiomyopathy Care
- Ahmad Masri, MD, MS
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
Cardiology
TTR Levels and Associated Disease Risk: Insights from 2025 PNS Conference
- Ahmad Masri, MD, MS
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
CME/CE
Optimize Outcomes in CKD & T2D: A Practical Approach to Initiating and Monitoring Combination ns-MRA & SGLT2i Therapy
0.25 credits
- Amy Mottl, MD, MPH
- Prof. Christoph Wanner
0.25 credits
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
Cardiology
ECG Markers as Predictors of Adverse Outcomes in COPD: Insights from the IMPACT Trial
- Raymond Wade, MD

8/11

113-128 of 306

Title

Welcome to Global Cardiology Academy

Welcome to Global
Cardiology Academy